Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Akari Therapeutics PLC (AKTX : NSDQ)
 
 • Company Description   
Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.17 Daily Weekly Monthly
20 Day Moving Average: 26,640 shares
Shares Outstanding: 32.18 (millions)
Market Capitalization: $37.65 (millions)
Beta: 0.21
52 Week High: $4.40
52 Week Low: $0.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.74% -13.68%
12 Week 5.41% -11.57%
Year To Date -4.10% -10.17%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
22 BOSTON WHARF ROAD FL 7
-
BOSTON,MA 02210
GBR
ph: 929-274-7510
fax: 646-843-9352
info@akaritx.com http://www.akaritx.com
 
 • General Corporate Information   
Officers
Samir R. Patel - President and Chief Executive Officer
Hoyoung Huh - Chairman
Torsten Hombeck - Chief Financial Officer
Ray Prudo - Director
James Neal - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00972G207
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/18/25
Share - Related Items
Shares Outstanding: 32.18
Most Recent Split Date: 8.00 (0.05:1)
Beta: 0.21
Market Capitalization: $37.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/18/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.55
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -213.59
12/31/24 - -956.20
ROA
06/30/25 - -
03/31/25 - -65.60
12/31/24 - -129.47
Current Ratio
06/30/25 - -
03/31/25 - 0.16
12/31/24 - 0.15
Quick Ratio
06/30/25 - -
03/31/25 - 0.16
12/31/24 - 0.15
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.75
12/31/24 - 0.84
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©